Sertoli-Leydig cell tumour
From Wikipedia, the free encyclopedia
| Sertoli-Leydig cell tumour Classification and external resources |
|
| ICD-9 | 183.0, 256.1 |
|---|---|
| ICD-O: | 8631/0 |
| Arrhenoblastoma Classification and external resources |
|
| ICD-O: | 8630 |
|---|---|
Sertoli-Leydig cell tumour, also known as arrhenoblastoma or androblastoma, is a member of the sex cord-stromal tumour group of ovarian and testicular cancers. The tumour is rare, comprising less than 1% of ovarian tumours,[citation needed]. While the tumour can occur at any age, it occurs most often in young adults.
Contents |
[edit] Classification
The tumour is subdivided into many different subtypes. The most typical is composed of tubules lined by Sertoli cells and interstitial clusters of Leydig cells.
[edit] Presentation
Due to excess testosterone secreted by the tumour, one-third of female patients present with a recent history of progressive masculinization. Masculinization is preceded by anovulation, oligomenorrhea, amenorrhea and defeminization. Additional signs include acne and hirsutism, voice deepening, clitoromegaly, temporal hair recession, and an increase in musculature. Serum testosterone level is high.
[edit] Diagnosis
A recent study has shown that CD56 can be a marker for tumors of this class.[1]
[edit] Treatment
Treatment consists of surgical resection alone with a unilateral salpingo-oophorectomy. The prognosis is generally good as the tumour tends to grow slowly and usually is benign: 25% are malignant.[citation needed]
[edit] References
- ^ McCluggage WG, McKenna M, McBride HA (2007). "CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors". Int. J. Gynecol. Pathol. 26 (3): 322–7. doi:. PMID 17581419.
|
||||||||||||||||||||||||||||||||
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
